open access

Ahead of print
Original Paper
Published online: 2020-06-26
Submitted: 2020-02-18
Accepted: 2020-06-02
Get Citation

Low Serum Levels of Meteorin-like/Subfatin: An Indicator of Diabetes Mellitus and Insulin Resistance?

Erhan Onalan, Cundullah Cavlı, Yusuf Dogan, Ebru Onalan, Nevzat Gozel, Ilay Buran, Burkay Yakar, Emir Donder
DOI: 10.5603/EP.a2020.0038
·
Pubmed: 32598020

open access

Ahead of print
Original Paper
Published online: 2020-06-26
Submitted: 2020-02-18
Accepted: 2020-06-02

Abstract

Aim: Meteorin-like (Metrnl), also known as subfatin, is a recently discovered adipokine with a favorable effect on insulin sensitivity. Studies have shown lower Metrnl levels in obese patients. However, data on its circulating levels in type 2 diabetes mellitus (T2DM) patients are contradictory. This study aims to evaluate serum Metrnl levels in T2DM patients and determine the relationship between serum Metrnl levels and insulin resistance in these patients. Materials and Methods: Our study included 50 patients recently diagnosed with T2DM who were not on medical treatment, 50 long-standing Type 2 DM patients who were on medical treatment, and 50 healthy individuals as control subjects. Serum levels of subfatin were measured using the ELISA method. Results: Serum levels of subfatin were determined as 21.1 ± 17 for the healthy control group, as 5.6 ± 14.5 for the recently diagnosed diabetic group, and as 2.81 ± 2.85 for the long-standing diabetic group on medical treatment, and there was a strong statistically significant difference between the groups (< 0.001). Conclusions: Serum levels of subfatin show a gradual decrease from healthy individuals to more advanced stages of diabetes, suggesting that it can serve as a useful marker in the prediabetic period in individuals with risk factors for diabetes.

Abstract

Aim: Meteorin-like (Metrnl), also known as subfatin, is a recently discovered adipokine with a favorable effect on insulin sensitivity. Studies have shown lower Metrnl levels in obese patients. However, data on its circulating levels in type 2 diabetes mellitus (T2DM) patients are contradictory. This study aims to evaluate serum Metrnl levels in T2DM patients and determine the relationship between serum Metrnl levels and insulin resistance in these patients. Materials and Methods: Our study included 50 patients recently diagnosed with T2DM who were not on medical treatment, 50 long-standing Type 2 DM patients who were on medical treatment, and 50 healthy individuals as control subjects. Serum levels of subfatin were measured using the ELISA method. Results: Serum levels of subfatin were determined as 21.1 ± 17 for the healthy control group, as 5.6 ± 14.5 for the recently diagnosed diabetic group, and as 2.81 ± 2.85 for the long-standing diabetic group on medical treatment, and there was a strong statistically significant difference between the groups (< 0.001). Conclusions: Serum levels of subfatin show a gradual decrease from healthy individuals to more advanced stages of diabetes, suggesting that it can serve as a useful marker in the prediabetic period in individuals with risk factors for diabetes.

Get Citation

Keywords

Subfatin/meteorin-like, type 2 diabetes mellitus, insulin resistance

About this article
Title

Low Serum Levels of Meteorin-like/Subfatin: An Indicator of Diabetes Mellitus and Insulin Resistance?

Journal

Endokrynologia Polska

Issue

Ahead of print

Published online

2020-06-26

DOI

10.5603/EP.a2020.0038

Pubmed

32598020

Keywords

Subfatin/meteorin-like
type 2 diabetes mellitus
insulin resistance

Authors

Erhan Onalan
Cundullah Cavlı
Yusuf Dogan
Ebru Onalan
Nevzat Gozel
Ilay Buran
Burkay Yakar
Emir Donder

References (16)
  1. Diagnosis, Classification and Screening in Glycemic Disorders. TEMD Guidelines for Diagnosis, Treatment and Follow-up of Diabetes Mellitus and Complications. 9th ed. Turkish Endocrinology and Metabolism Association 2017.
  2. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep. 2002; 4(2): 105–111.
  3. Li ZY, Zheng SL, Wang P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014; 20(4): 344–354.
  4. Jørgensen JR, Fransson A, Fjord-Larsen L, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. 2012; 233(1): 172–181.
  5. Zheng SL, Li ZY, Song J, et al. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016; 37(5): 571–579.
  6. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157(6): 1279–1291.
  7. Li ZY, Song J, Zheng SL, et al. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes. 2015; 64(12): 4011–4022.
  8. Ushach I, Burkhardt AM, Martinez C, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015; 156(2): 119–127.
  9. Dadmanesh M, Aghajani H, Fadaei R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018; 13(9): e0204180.
  10. Fadaei R, Dadmanesh M, Moradi N, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2018 [Epub ahead of print]: 1–6.
  11. Chung HS, Hwang SY, Choi JuH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018; 136: 100–107.
  12. Wang K, Li F, Wang C, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019; 25: 2337–2343.
  13. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep. 2002; 4(2): 105–111.
  14. Lee JuH, Kang YE, Kim JiM, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract. 2018; 135: 7–10.
  15. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018; 42(4): 919–922.
  16. Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017; 41(1): 112–119.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl